Table 1. Comparisons of clinicopathological characteristics in IBCs between the LNM– and LNM+ groups.
| Clinicopathological features | LNM– (n=114) | LNM+ (n=109) | P value |
|---|---|---|---|
| Age (years) | 55.06±10.24 | 55.10±10.24 | 0.984 |
| Size (mm) | 23.93±10.39 | 27.17±9.82 | 0.018 |
| Tumor type | 0.735 | ||
| Classified | 89.47% (n=102) | 90.83% (n=99) | |
| Specified | 10.53% (n=12) | 9.17% (n=10) | |
| Lymphovascular invasion | <0.001 | ||
| Present | 13.16% (n=15) | 34.86% (n=38) | |
| Absent | 86.84% (n=99) | 65.14% (n=71) | |
| ER | 0.259 | ||
| Positive | 75.44% (n=86) | 81.65% (n=89) | |
| Negative | 24.56% (n=28) | 18.35% (n=20) | |
| PR | 0.259 | ||
| Positive | 75.44% (n=86) | 81.65% (n=89) | |
| Negative | 24.56% (n=28) | 18.35% (n=20) | |
| HER2 | |||
| Positive | 38.60% (n=44) | 33.03% (n=36) | 0.386 |
| Negative | 61.40% (n=70) | 66.97% (n=73) | |
| Ki-67 | 0.016 | ||
| <14% | 32.46% (n=37) | 18.35% (n=20) | |
| ≥14% | 67.54% (n=77) | 81.65% (n=89) | |
| Intrinsic subtypes | 0.887 | ||
| Luminal A | 11.40% (n=13) | 13.76% (n=15) | |
| Luminal B | 67.54% (n=77) | 68.81% (n=75) | |
| HER2 | 8.77% (n=10) | 7.34% (n=8) | |
| Basal like | 12.28% (n=14) | 10.09% (n=11) | |
| p53 | 0.169 | ||
| Present | 71.05% (n=81) | 62.39% (n=68) | |
| Absent | 28.95% (n=33) | 37.61% (n=41) | |
| CK5/6 | 0.588 | ||
| Present | 19.30% (n=22) | 16.51% (n=18) | |
| Absent | 80.70% (n=92) | 83.49% (n=91) | |
| E-cadherin | 0.108 | ||
| Present | 92.11% (n=105) | 85.32% (n=93) | |
| Absent | 7.89% (n=9) | 14.68% (n=16) | |
| CA153 (ng/mL) | 11.72±7.05 | 11.21±4.70 | 0.68 |
| CEA (ng/mL) | 3.96±7.83 | 2.11±2.07 | 0.143 |
IBC, invasive breast cancer; LNM, axillary lymph node metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.